PROTECH HOME MEDICAL TO PARTICIPATE AT VIRTUAL INVESTOR CONFERENCES IN NOVEMBER SIDOTI WEBCASTED PRESENTATION TO BE HELD THURSDAY NOVEMBER 19
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN.
Cincinnati, Ohio – November 3, 2020 – Protech Home Medical Corp. (the “Company” or “Protech”) (TSXV: PTQ) (OTCQX: PTQQF), a U.S. based leader in the home medical equipment industry, focused on end-to-end respiratory care, today announced that members of its management team will participate in 1x1 meetings at the upcoming 9th Annual Benchmark Virtual Discovery One on One Investor Conference on November 18th, and the Sidoti Fall 2020 Virtual Microcap Conference on November 19th.
9th Annual Benchmark Virtual Discovery One on One Investor
will participate in the 9th Annual Benchmark Virtual Discovery One
on One Investor Conference on Wednesday, November 18, 2020.
Benchmark is a leading financial services
firm focused on investment banking, equity research, and sales & trading
within the Technology, Media, Healthcare and Industrial sectors. Founded in
1988, Benchmark is headquartered in New York City with offices in Boston,
Milwaukee and San Francisco.
For additional information or to schedule a one-on-one meeting at the 9th Annual Benchmark Virtual Discovery One on One Investor Conference on Wednesday, November 18, 2020, please contact Vince Curatola-Director of Corporate Marketing Services at firstname.lastname@example.org.
Sidoti Fall 2020 Virtual Microcap Conference
will participate in the Sidoti Fall 2020 Virtual Microcap Conference on
Thursday, November 19, 2020, which will be webcasted at 10:00am (EST).
The live webcast of the presentation will be
available by visiting the investors' section of the Company's website at www.protechhomemedical.com. The webcast will also be available for
replay on the Company's website following the event. Please visit the events
section of the Sidoti & Company website at https://sidoticonference.com to register for the conference and
schedule a one-on-one meeting.
“On the heels of closing Sleepwell, bringing our
run-rate revenue to $125 million, we continue to possess the strongest balance
sheet in our history with over $28 million in cash and an undrawn USD$20
million credit facility with CIT Bank. We have consistently hit revenue and
EBITDA margin milestones and have just revised our growth trajectory upward for
the next five years, making this an exciting time for our company and
shareholders,” commented Greg Crawford, CEO, and Chairman of Protech.
Furthermore, with the recent CMS decision to cancel the 2021 Competitive
Bidding Program for 13 product categories, reimbursement rates have likely neared a floor and
there is no Medicare reimbursement rate cut risks for the foreseeable future
which truly clears the margin outlook for us, and we believe this
news, coupled with our continued strong operating performance, will bode well
for our underlying results. We look forward to sharing our dynamic clinical
respiratory company with new U.S. based investors, in particular as we look to
significantly enhance our U.S. presence in 2021.”